A whistle blower reports poor compliance with Good Clinical Practice at a CRO managing 3 US sites in the Pfizer study.
There is no evidence that these errors would have undermined the scientific integrity of the trial results.
Example 1: needle disposal
/2
The Texas CRO being criticised was managed by large global CRO icon. The article tells us icon raised concerns about turn around time. This is the system working.
In any large clinical trial there are numerous little arrow made at sites. This trial was done at huge speed.
/3
And the paper spends a lot of time discussing FDA inspections.
What do we learn? The CRO was clearly aware there were GCP issues that an FDA inspection would find.
And we are told "corrective action" was undertaken.
Also a good sign that management was aware and acting.
/4
Anyone who has ever been involved in a large complex clinical trial knows errors are made. The regulations are all about putting in place systems and documentation to help reduce the errors, spot them, and correct them when they happen.
Going fast stresses the system.
/6
The covid vaccines were developed at speed in a pandemic. That inevitably put everyone and everything under pressure.
It is no surprise that speed resulted in some compliance issues and that staff were working outside of their comfort zone.
/7
The key question is : were any of these issues serious enough to undermine the scientic integrity of the trial results?
The paper does not all claim that they did.
How does the paper end?
/8
Well we learn at the end of the paper that the study Sponsor (Pfizer) conducted an audit and clearly was sufficiently happy with the data quality and CRO performance that used the company again.
This is a non story.
But it will be abused by anti-vaxxers.
/9
This is a story of a CRO operating under pressure, with mistakes made, and some poor people management.
But nothing here justifies the sort of anti-vaxx comments the BMJ tweet has generated.
Or why I think it is wrong to say say "we can't know vaccines are safe, because just look how long it took to discover the harm from smoking, x-rays, asbestos".
/
The "it is too soon to know it is safe" argument initially seems quite rational, and is the foundation of much vaccine hesitancy and widespread in anti-vaccine literature.
I don't want to focus on rebutting claims about the science, but to consider process and implications.
/
There are two levels of protection we as members of the public have against unsafe vaccines.
1. medicines regulators (FDA, EMA, MHRA etc) that determine if they are safe and effective
2. vaccine authorities that decide whether universal vaccination is justified.
Great to be at an in person médical conference, on Alzheimers disease, in Boston. This particular conference was founded in 2008.
Quite some excitement that we are now in the therapeutic era for AD.
But so striking the conference kicked off by a panel of old men.
/1
It is notable how the leaders of the field haven't really changed in 13 years. Some have died of course. But leadership seems very unrepresentative of the research base.
It is about time conference organizes avoided keynote panels limited to old white men.
/2
And we now get @jasonkarlawish who has criticised the FDA accelerated approve of aducanumab.
"we have set a new standard [for approval] that people don't quite believe in".
He is speaking remotely. Hopefully not because he would have felt uncomfortable here.
Once again medicines regulations are becoming politically charged in the UK. Late last year it was rapid / hasty (depending in your view) MHRA authorization of COVID vaccines. Now it is about cancer treatments.
Brief thread on regulatory approval and market access.
/1
For your doctor to prescribe you a medicine, two things must be true (outside a clinical trial)
1. The medicine can legally be sold in the place you live (regulatory marketing authorization) 2. Someone (hopefully by you) is willing to pay for that medicine (reimbursement)
/2
The regulators make sure that medicines are only sold if there is strong evidence that the balance of benefit to risk is favourable. Their goal is to stop companies marketing medicines that are unsafe or don't work.
Tough choices for governments in managing COVID-19.
With apologies to @olivierveran here are some sketches which I think illustrate options. We are plotting number of cases on y against time on x.
Firstly the do nothing option is the blue curve in this graph.
The reason that is so bad is that at peak the number if cases would be well above the capacity - red line - of the healthcare system to cope. Insufficent ventilators, beds and staff would lead to higher proportion of cases dying than would otherwise be the case.
/2
Govs want to "flatten the curve" so cases develop like the green curve. Even if the total number of cases were the same as in the blue curve, the fatality rate would be lower as hospitals could cope better: the max number of cases never exceeds healthcare capacity red line).
/3